argenx SE (NASDAQ:ARGX) Receives $390.67 Average Target Price from Analysts

Shares of argenx SE (NASDAQ:ARGXGet Rating) have earned an average recommendation of “Buy” from the eighteen brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, fourteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $390.67.

ARGX has been the subject of a number of research reports. Stifel Nicolaus upped their target price on shares of argenx from $460.00 to $471.00 in a report on Thursday, July 28th. HC Wainwright upped their target price on shares of argenx from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Friday, July 29th. SVB Leerink boosted their price target on shares of argenx from $404.00 to $428.00 and gave the company an “outperform” rating in a research report on Friday, July 29th. JPMorgan Chase & Co. boosted their price target on shares of argenx from €390.00 ($402.06) to €430.00 ($443.30) and gave the company an “overweight” rating in a research report on Thursday, July 14th. Finally, Robert W. Baird reissued a “downgrade” rating on shares of argenx in a research report on Friday, July 29th.

argenx Stock Down 0.3 %

argenx stock opened at $367.85 on Monday. argenx has a 52-week low of $249.50 and a 52-week high of $387.89. The company has a fifty day simple moving average of $353.35 and a 200-day simple moving average of $316.84.

argenx (NASDAQ:ARGXGet Rating) last released its earnings results on Thursday, May 5th. The company reported ($4.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($5.07) by $0.71. argenx had a negative net margin of 538.17% and a negative return on equity of 49.45%. The business had revenue of $31.48 million during the quarter, compared to analyst estimates of $12.68 million. During the same quarter in the prior year, the firm earned ($0.81) earnings per share. Equities analysts anticipate that argenx will post -15.89 EPS for the current fiscal year.

Institutional Trading of argenx

Institutional investors have recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. raised its position in argenx by 1,055.8% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 10,009 shares of the company’s stock valued at $3,792,000 after buying an additional 9,143 shares during the period. Glassman Wealth Services increased its position in argenx by 69.4% in the 2nd quarter. Glassman Wealth Services now owns 83 shares of the company’s stock worth $31,000 after purchasing an additional 34 shares during the last quarter. Steward Partners Investment Advisory LLC increased its position in argenx by 71.3% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 298 shares of the company’s stock worth $113,000 after purchasing an additional 124 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of argenx by 3.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 13,511 shares of the company’s stock worth $5,119,000 after acquiring an additional 499 shares in the last quarter. Finally, Assetmark Inc. boosted its stake in shares of argenx by 40.4% during the 2nd quarter. Assetmark Inc. now owns 2,094 shares of the company’s stock worth $793,000 after acquiring an additional 603 shares in the last quarter. Institutional investors and hedge funds own 58.76% of the company’s stock.

About argenx

(Get Rating)

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study.

See Also

Analyst Recommendations for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.